Expect significant downward pressure from the dilutive offering and warrant overhang. Monitor the registration statement filing and any updates on FemBloc clinical progress, as milestone warrant conditions require revenue and stock price thresholds that may not be met. The stock has historically declined ~25% over 20 days following recent filings, and this event is more negative than those.
Price Chart
Executive Summary
Femasys announced a $30 million private placement led by Nantahala Capital, selling 9.37M shares and warrants for 18.75M additional shares at $3.20 per share. The offering is ~3.3x the company's $9M market cap, causing massive dilution and warrant overhang. The stock has declined ~25% on average over 20 days following recent filings, and this dilutive event is likely to pressure shares further.
Key Financial Metrics
Key Facts
- $30 million private placement led by Nantahala Capital with participation from Rosalind Advisors and management
- 9,374,999 shares of common stock (or pre-funded warrants) plus two accompanying warrants for each share, totaling 18,749,998 warrant shares
- Purchase price $3.20 per share; warrants exercisable at $2.95 per share for three years
- Milestone warrants require $1.5M quarterly U.S. revenue and 130% of exercise price stock price for 20 of 30 days
- Potential additional $60 million if all warrants exercised for cash
- Expected closing on or around August 10, 2026
Financial Impact
Offering size of $30M is approximately 333% of the $9M market cap, implying extreme dilution. Full warrant exercise could add another $60M in proceeds but further dilute by up to 18.75M shares.
Risk Factors
- Massive dilution from 9.37M new shares and up to 18.75M warrant shares
- Warrant overhang at $2.95 exercise price may cap upside
- Milestone warrants unlikely to vest given current revenue base (below $1.5M quarterly)
- Cash burn rate unknown; $30M may only provide limited runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341129 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $1.67 | awaiting T+5 | — | $1.41 (−15.57%) |
Oct 15, 2026 11d ago | SC 13G | $1.74 $1.56 | ▼ −10.09% | ▼ −9.07% | $1.41 (−18.73%) |
Sep 29, 2026 28d ago | EFFECT | $2.09 $2.08 | ▲ +0.48% | ▲ +2.43% | $1.41 (+32.54%) |
Aug 14, 2026 10w ago | 8-K | $2.16 $2.98 | ▼ −37.96% | ▼ −39.15% | $1.41 (+34.72%) |
Aug 14, 2026 10w ago | Press Release | $2.16 $2.98 | ▲ +37.96% | ▲ +39.15% | $1.41 (−34.72%) |
Aug 11, 2026 10w ago | Insider Cluster | $2.35 $2.71 | ▲ +15.32% | ▲ +15.76% | $1.41 (−40.00%) |
Aug 7, 2026 11w ago | Press Release | $2.66 $2.29 | ▲ +13.91% | ▲ +14.31% | $1.41 (+46.99%) |
Jun 4, 2026 20w ago | 8-K | $7.14 $4.78 | ▼ −33.05% | ▼ −30.50% | $1.41 (−80.25%) |
May 13, 2026 23w ago | 8-K | $7.61 $6.75 | ▼ −11.38% | ▼ −10.66% | $1.41 (−81.48%) |
May 8, 2026 24w ago | 8-K | $8.08 $7.26 | ▼ −10.24% | ▼ −10.16% | $1.41 (−82.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers